Literature DB >> 24798146

Soluble Lectin-Like Oxidized LDL Receptor 1 as a Possible Mediator of Endothelial Dysfunction in Patients With Metabolic Syndrome.

S Civelek1, M Kutnu1, H Uzun1, F Erdenen2, E Altunoglu2, G Andican1, A Seven1, A O Sahin1, G Burcak1.   

Abstract

BACKGROUND: Metabolic syndrome (MetS) defines a well-known cluster of metabolic disturbances associated with an increased risk of cardiovascular disease and diabetes. The aim of this study was to examine the distribution of soluble lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (sLOX-1) levels in patients with MetS, possible association of sLOX-1 with oxidized LDL (oxLDL), endothelial nitric oxide synthase (eNOS), nitric oxide (NOx), endothelin-1 (ET-1), paraoxonase 1 (PON1), and arylesterase (ARE) activities, and these parameters compared with healthy controls.
METHODS: A total of 55 patients (37 women, 18 men) with MetS and 29 healthy controls (19 women, 10 men) with a body mass index (BMI) less than 25 kg/m(2) were enrolled in the study.
RESULTS: sLOX-1, oxLDL, and ET-1 levels were significantly higher in patients with MetS than in control subjects (P = 0.023 P < 0.001, and P < 0.001, respectively). MetS patients have significantly lower eNOS and NOx levels, and PON1 and ARE activities than control subjects (P = 0.017, P < 0.004, P < 0.001, and P = 0.010, respectively). A positive correlation was observed between the sLOX-1 levels and the oxLDL, ET-1, BMI, glucose levels. ET-1 levels also exhibited significant negative correlation with ARE activity.
CONCLUSION: sLOX-1 levels are associated with cardiovascular risk factors, such as increased oxLDL, obesity, and diabetes, in patients with MetS. An increased concentration of sLOX-1 could be an early predictor of endothelial damage in MetS. In addition, it appears that oxLDL, ET-1, eNOS, NOx, PON1, and ARE activities may accurately reflect the levels of endothelial dysfunction in MetS patients.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  endothelial nitric oxide synthase; endothelin-1; metabolic syndrome; nitric oxide; oxidized LDL; soluble lectin-like oxidized LDL receptor 1

Mesh:

Substances:

Year:  2014        PMID: 24798146      PMCID: PMC6806729          DOI: 10.1002/jcla.21748

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  35 in total

1.  Circulating levels of adiponectin, orexin-A, ghrelin and the antioxidant paraoxonase-1 in metabolic syndrome.

Authors:  O Tabak; R Gelişgen; H Cicekçi; E Senateş; F Erdenen; C Müderrisoğlu; H Aral; H Uzun
Journal:  Minerva Med       Date:  2012-08       Impact factor: 4.806

Review 2.  The metabolic syndrome - an ongoing story.

Authors:  L Duvnjak; M Duvnjak
Journal:  J Physiol Pharmacol       Date:  2009-12       Impact factor: 3.011

3.  [LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis].

Authors:  H Morawietz
Journal:  Dtsch Med Wochenschr       Date:  2010-02-09       Impact factor: 0.628

4.  Weight reduction can decrease circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in overweight middle-aged men.

Authors:  Yasuhiro Nomata; Noriaki Kume; Hiroyuki Sasai; Yasutomi Katayama; Yoshio Nakata; Tomohiro Okura; Kiyoji Tanaka
Journal:  Metabolism       Date:  2009-07-09       Impact factor: 8.694

5.  Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.

Authors:  Dubravka Juretić; Alena Motejlkova; Branka Kunović; Branka Rekić; Zlata Flegar-Mestrić; Lovorka Vujić; Ranko Mesić; Jana Lukac-Bajalo; Vera Simeon-Rudolf
Journal:  Acta Pharm       Date:  2006-03       Impact factor: 2.230

6.  Elevated soluble lectin-like oxidized LDL receptor-1 (sLOX-1) levels in obese postmenopausal women.

Authors:  Tina E Brinkley; Noriaki Kume; Hirokazu Mitsuoka; Dana A Phares; James M Hagberg
Journal:  Obesity (Silver Spring)       Date:  2008-04-03       Impact factor: 5.002

Review 7.  Lectin-like oxidized low-density lipoprotein receptor 1 pathways.

Authors:  Ashraf Taye; Azza A K El-Sheikh
Journal:  Eur J Clin Invest       Date:  2013-04-18       Impact factor: 4.686

8.  Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus.

Authors:  Kathryn C B Tan; Sammy W M Shiu; Ying Wong; Lin Leng; Richard Bucala
Journal:  J Lipid Res       Date:  2008-04-12       Impact factor: 5.922

Review 9.  Endothelial dysfunction in metabolic syndrome.

Authors:  Angela Cozma; Olga Orăşan; D Sâmpelean; Adriana Fodor; C Vlad; V Negrean; N Rednic; D Zdrenghea
Journal:  Rom J Intern Med       Date:  2009

10.  Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease.

Authors:  Nicola Martinelli; Roberta Micaglio; Letizia Consoli; Patrizia Guarini; Elisa Grison; Francesca Pizzolo; Simonetta Friso; Elisabetta Trabetti; Pier Franco Pignatti; Roberto Corrocher; Oliviero Olivieri; Domenico Girelli
Journal:  Exp Diabetes Res       Date:  2011-09-22
View more
  4 in total

1.  Endothelin-1 and LOX-1 as Markers of Endothelial Dysfunction in Obstructive Sleep Apnea Patients.

Authors:  Monika Kosacka; Anna Brzecka
Journal:  Int J Environ Res Public Health       Date:  2021-02-01       Impact factor: 3.390

Review 2.  Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics.

Authors:  Jonathan De Siqueira; Izma Abdul Zani; David A Russell; Stephen B Wheatcroft; Sreenivasan Ponnambalam; Shervanthi Homer-Vanniasinkam
Journal:  J Cardiovasc Transl Res       Date:  2015-09-18       Impact factor: 4.132

3.  Membrane Cholesterol Modulates LOX-1 Shedding in Endothelial Cells.

Authors:  Magda Gioia; Giulia Vindigni; Barbara Testa; Sofia Raniolo; Giovanni Francesco Fasciglione; Massimiliano Coletta; Silvia Biocca
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

4.  Soluble LOX-1: A Novel Biomarker in Patients With Coronary Artery Disease, Stroke, and Acute Aortic Dissection?

Authors:  Anja Hofmann; Coy Brunssen; Steffen Wolk; Christian Reeps; Henning Morawietz
Journal:  J Am Heart Assoc       Date:  2020-01-04       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.